Cellosaurus MES-SA (CVCL_1404)

Cell line name MES-SA
Synonyms MESSA
Accession CVCL_1404
Resource Identification Initiative To cite this cell line use: MES-SA (RRID:CVCL_1404)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Doubling time: 22-24 hours (ECACC).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Disease Uterine corpus sarcoma (NCIt: C6339)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_4T93 (MES-SA/Dx1); CVCL_2598 (MES-SA/Dx5); CVCL_2599 (MES-SA/MX2)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ECACC; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11
D13S31711,13
D16S53911,12
D18S5112,15
D19S43314.2,15
D21S1129,30.2
D2S133817
D3S135814,17
D5S81813
D7S8207,11
D8S117914,15
FGA20,25
Penta D13,15
Penta E7,10
TH016
TPOX8,11
vWA18
Web pages http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-490.html
http://tcpaportal.org/mclp/
Publications

PubMed=6883344
Harker W.G., MacKintosh F.R., Sikic B.I.
Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs.
Cancer Res. 43:4943-4950(1983)

PubMed=22889595; DOI=10.1016/j.jprot.2012.07.047
Lin S.-T., Chou H.-C., Chang S.-J., Chen Y.-W., Lyu P.-C., Wang W.-C., Chang M.D.-T., Chan H.-L.
Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells.
J. Proteomics 75:5822-5847(2012)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-1976
BCRC; 60333
ECACC; 95051030
ICLC; HTL96008
Cell line databases/resources CLDB; cl3447
CLDB; cl3448
CCLE; MESSA_SOFT_TISSUE
Cosmic-CLP; 908127
GDSC; 908127
IGRhCellID; MESSA
LINCS_LDP; LCL-1509
Ontologies CLO; CLO_0007677
EFO; EFO_0002233
Biological sample resources BioSample; SAMN03470984
Chemistry resources ChEMBL-Cells; CHEMBL3307599
ChEMBL-Targets; CHEMBL614343
Gene expression databases GEO; GSM827389
GEO; GSM1670096
GEO; GSM1676304
GEO; GSM1701639
Polymorphism and mutation databases Cosmic; 687553
Cosmic; 848889
Cosmic; 908127
Cosmic; 2008739